Find Clinical Trials
INES – Phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with oestrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer.
Servier Protocol Code:
CL1-80881-002
Sponsor:
Institut de Recherches Internationales Servier (I.R.I.S)
EudraCT Number:
2013-001520-19
Find a recruiting site
Name:
Institut de Recherches Internationales Servier, Département des études cliniques
Phone number:
+33 1 55 72 60 00
Results
English (USA)Interventions / Treatments
The treatment(s) given to the participants in the study.
- Solid tumors
- LUCITANIB
- S080881
Other study id numbers
Other identification numbers the study may be known by.
- CL1-80881-002